Clinical trial Recruiting at 1 site Observational Ages 65 and up

Early post-op blood biomarkers and the risk of delirium after major surgery

Official title: The Association Between Postoperative Inflammatory and Neuroogical Serum Biomarker Concentrations and Occurrence of Postoperative Delirium - a Prospective Observational Study

Run by Medical University of Vienna · NCT07411612 · Data updated 2026-11-12

We will test whether blood levels of S100B, NSE, IL-6, and Copeptin measured within two hours after surgery can help predict delirium in people 65 and older having major non-cardiac, non-intracranial, non-vascular elective surgery.

More Postoperative Complications trials

Quick facts

Study typeObservational
Ages65 Years and up
SexAll
Enrollment1170 (estimated)
SponsorMedical University of Vienna
Academic / other
Locations1 site (Vienna)
StatusRecruiting
StartedJanuary 12, 2026
Main results expectedJanuary 15, 2030
Study endsJanuary 18, 2030
Registry record updatedFebruary 17, 2026
Trial IDNCT07411612 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 65 or older who can give consent and are scheduled for elective major non-cardiac, non-intracranial, non-vascular surgery expected to last two hours or more, without a history of dementia or preoperative delirium.

Probably not a fit

Patients undergoing emergency surgery, those with diagnosed dementia or preoperative delirium, ICU surgery patients, or those with language/vision/hearing limitations preventing cognitive assessment are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational cohort study enrolling patients aged 65 and older undergoing elective major non-cardiac, non-intracranial, non-vascular surgery lasting at least two hours. Blood samples taken within two hours after surgery will be analyzed for S100B, NSE, IL-6, and Copeptin concentrations. Participants will be monitored for postoperative delirium during the first three postoperative days using validated tools (3D-CAM or CAM-ICU). The primary aim is to test the association between early postoperative S100B levels and delirium occurrence, with secondary analyses for NSE, IL-6, and Copeptin and their predictive value. Patients with dementia, preoperative delirium, emergency procedures, or sensory/language barriers are excluded.

Why it matters

Potential benefit: If successful, a simple early blood test could identify patients at high risk for postoperative delirium so clinicians can increase monitoring and apply preventive measures.

How similar studies have gone: Previous studies have reported associations between some of these biomarkers and delirium but results have been mixed and predictive accuracy remains uncertain.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Provide written informed consent
* ≥ 65 years of age
* Scheduled for elective major non-cardiac, non-intrcranial, non-vascular surgery with estimated time of surgery ≥ 2 hours

Exclusion Criteria:

* Patients undergoing emergency surgery
* History of diagnosed dementia
* Language, vision, or hearing impairments that may compromise cognitive assessments
* Preoperative delirium
* ICU patients undergoing surgery

Where it's running

  • Medical University of Vienna
    Vienna, Austria
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.